Skip to main content

Table 1 Effect of SGLT2 inhibitors on clinical outcomes in adults with diabetic kidney disease

From: Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis

Outcome No. studies No. events Sample size HR (95% CI) I2, % PHeterogeneity PEgger test
MACE 6 2271 21,913 0.83 (0.75–0.93) 33.8 0.183 0.287
Kidney composite 5 1197 21,195 0.66 (0.58–0.75) 0.0 0.949 0.513
HHF 6 1219 22,346 0.62 (0.55–0.71) 0.0 0.844 0.267
Cardiovascular death 5 953 20,539 0.84 (0.74–0.96) 0.0 0.639 0.996
Fatal and nonfatal MI 5 498* 20,108 0.78 (0.67–0.92) 7.7 0.363 0.671
Fatal and nonfatal stroke 5 332* 20,108 0.76 (0.59–0.97) 41.3 0.146 0.564
All-cause mortality 5 1451 21,406 0.86 (0.77–0.96) 14.5 0.322 0.268
  1. *The number of MI events and stroke cases from the SCORED trial were not reported in the primary trials and are not included in the table. CI indicates confidence interval; HHF hospitalization for heart failure, HR hazard ratio, I2, I-squared, MACE Major Adverse Cardiovascular Events, MI myocardial infarction, SCORED Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk, SGLT2 sodium-glucose cotransporter 2; SGLT2, sodium-glucose cotransporter 2, SOLOIST-WHF Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure, VERTIS CV Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial